Carrington’s GelSite will be tested on Nastech’s peptide and protein therapeutics in liquid formulations.
Carrington Laboratories’ wholly owned subsidiary, DelSite Biotechnologies, entered into a non-exclusive technology evaluation agreement with Nastech Pharmaceutical for the purpose of evaluating DelSite’s GelSite polymer for enhancing intranasal delivery of peptide and protein therapeutics.
The goal of the program is to assess whether the GelSite polymer, in combination with Nastech’s tight junction modulating technology, can increase bioavailability and provide additional pharmacokinetic profiles that could be useful for future development of Nastech’s intranasally delivered peptides and proteins. As part of the agreement, DelSite will conduct initial formulation development of the GelSite polymer with Nastech formulations and will provide Nastech with final formulation characterization support.
GelSite polymer is a novel, naturally occurring, mucoadhesive ionic carbohydrate polymer capable of forming a gel when brought into contact with nasal fluids. Gelling occurs with liquid as well as powder formulations and provides sustained release and prolonged nasal residence time that may enhance the nasal delivery of therapeutics or vaccines, according to the company.
